查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049681

抗風濕藥物市場報告：按類型、藥物類別、給藥途徑、分銷管道和地區分類（2026-2034 年）

Anti-Rheumatics Market Report by Type, Drug Class, Route of Drug Administration, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球抗風濕藥物市場規模達676億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到820億美元，2026年至2034年的複合年成長率為2.10%。市場成長的主要促進因素包括全球人口老化、醫院、診所和其他醫療機構的擴張，以及大型製藥公司與醫療中心之間日益增加的合作。

抗風濕藥物是用來治療影響關節、肌肉和結締組織的疾病的藥物。它們有助於減輕發炎、疼痛和僵硬，並延緩疾病進展。抗風濕藥物種類繁多，包括非類固醇消炎劑（NSAIDs）、緩解疾病抗風濕藥（DMARDs）和生物製藥。這些藥物可靜脈注射。它們作用於導致組織損傷和發炎的潛在機制。通常，醫生會在進行全面診斷後開立處方，並合併用藥以達到最佳療效。

不健康的飲食習慣和缺乏運動導致風濕性疾病盛行率不斷上升，這是推動人們對有效治療方法需求的主要動力。此外，藥物遞送系統（例如奈米顆粒載體和緩釋膠囊）的持續發展，正在提高抗風濕藥物的療效和便利性。同時，遠端醫療服務的擴展有助於改善疾病管理和處方箋更新，從而促進抗風濕藥物的持續使用。此外，醫療保健系統向新興市場的擴展，使醫療服務不足的人口更容易獲得抗風濕藥物。最後，基因組學和個人化醫療的進步，使得更有針對性的治療成為可能，進一步提高了抗風濕藥物的療效。

抗風濕藥物市場的趨勢與促進因素：

人口老化的過程

老年人口的不斷成長，尤其是易患骨關節炎和類風濕性關節炎等關節疾病的老年人，是推動市場成長的主要因素之一。此外，老年人往往伴隨多種健康問題，這會加重風濕性疾病，需要更複雜、更長期的治療方案。世界各國政府和醫療衛生系統也意識到這一日益成長的需求，並正在增加醫療預算以應對老齡化社會帶來的挑戰。製藥公司也正集中研發力量，致力於開發更有效、更安全的抗風濕藥物。因此，預計未來幾年此類藥物的市場將顯著成長。

策略聯盟、併購

製藥公司與醫療機構之間策略聯盟、併購活動的增加是推動市場成長的另一個主要因素。這些活動通常涉及知識共用協議，有助於克服監管障礙，並縮短新藥上市時間。此外，大型製藥公司與生技新創公司之間不斷擴大的合作關係正在加速新型抗風濕藥物的研發和商業化。同時，研發活動也積極推進，以推出更先進的藥物。此外，這些合作關係還有助於將抗風濕藥物順利供應到先前尚未開發的市場，從而促進全球市場的成長。

提高對早期診斷和預防的認知

人們對早期診斷和預防類風濕性關節炎益處的認知不斷提高，正在推動市場成長。早期診斷有助於更有效地控制病情，並且在許多情況下，需要使用抗風濕藥物。此外，人們越來越依賴社群媒體來推廣醫學教育，這也對市場產生了正面影響。同時，多個國家行政部門發起的公共衛生宣傳活動也為市場創造了有利前景。此外，先進診斷工具的開發使醫療專業人員更容易早期識別風濕性疾病。這種積極主動的策略正在增加對抗風濕藥物的市場需求，因為及時介入需要藥物來控制症狀和緩解疾病。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球抗風濕藥物市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 處方藥
  • 非處方藥

第7章 市場區隔：依藥物類別分類

  • 緩解疾病抗風濕藥物（DMARDs）
  • 非類固醇消炎劑（NSAIDs）
  • 皮質類固醇
  • 降尿酸藥物
  • 其他

第8章 市場區隔：依給藥途徑

  • 口服
  • 腸外
  • 其他

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 電子商務

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AbbVie Inc.
    • Amgen Inc.
    • AstraZeneca plc
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • Celltrion Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnsons
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112026A4148

The global anti-rheumatics market size reached USD 67.6 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 82.0 Billion by 2034, exhibiting a growth rate (CAGR) of 2.10% during 2026-2034. The increasing aging population across the globe, expansion of hospitals, clinics, and other healthcare facilities, and the expanding partnerships between large pharmaceutical companies and healthcare centers are some of the major factors propelling the market growth.

Anti-rheumatics are medications used to treat diseases affecting the joints, muscles, and connective tissues. They help reduce inflammation, pain, and stiffness, and slow the progression of the disease. They are available in various classes, including non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), and biologics. They can be administered orally, subcutaneously and intravenously into the body. They target the underlying mechanisms that lead to tissue damage and inflammation. They are generally prescribed after a thorough diagnosis and are used in combination for optimum results.

The rising prevalence of rheumatic diseases due to unhealthy dietary patterns and lack of physical activity represent one of the key factors catalyzing the demand for effective treatments. Additionally, continuous development in drug delivery systems, like nanoparticle-based carriers or time-release capsules, is enhancing the efficacy and convenience of anti-rheumatic medications. Apart from this, the growth of telehealth services is enabling better disease management and easier prescription refills, promoting consistent use of anti-rheumatic drugs. Furthermore, the expansion of healthcare systems into emerging markets is making anti-rheumatic medications more accessible to underserved populations. Moreover, advancements in genomics and personalized medicine are allowing for more targeted treatments and improving the effectiveness of anti-rheumatic medications.

ANTI-RHEUMATICS MARKET TRENDS/DRIVERS:

Rising aging population

The increasing aging population, which is more susceptible to joint disorders, such as osteoarthritis and rheumatoid arthritis, represents one of the key factors augmenting the market growth. Moreover, older populations often have multiple health conditions that can exacerbate rheumatic diseases, thus requiring more complex and long-term treatment strategies. Additionally, governing authorities and healthcare systems of various countries are recognizing this growing need and are increasing healthcare budgets to address the challenges of an aging society. Pharmaceutical companies are also focusing their research and development efforts on creating more effective and safer anti-rheumatic medications. As a result, the market for these drugs is expected to grow substantially in the coming years.

Strategic collaborations and mergers

The increasing number of strategic collaborations, mergers, and acquisitions (M&A) among pharmaceutical companies and healthcare facilities is another major factor contributing to the market growth. They often include knowledge-sharing agreements, making it easier to navigate regulatory hurdles and reducing the time-to-market for new medications. Additionally, the expanding partnerships between large pharmaceutical companies and biotech startups result in the faster development and commercialization of new anti-rheumatic drugs. Apart from this, it facilitates research and development (R&D) activities to introduce more advanced drugs. Furthermore, these collaborations promote an easy supply of anti-rheumatic drugs to reach previously untapped markets, contributing to global market growth.

Rising awareness about early diagnosis and prevention

The rising awareness among individuals about the benefits of early diagnosis and prevention of rheumatoid diseases is strengthening the growth of the market. Early diagnosis allows for more effective management of the disease, often requiring the use of anti-rheumatic drugs. Additionally, the increasing reliance of people on social media channels promoting medical education is positively influencing the market. Furthermore, the governing authorities of several countries are organizing public health campaigns, which is offering a favorable market outlook. Moreover, the development of advanced diagnostic tools has made it easier for healthcare professionals to identify rheumatic diseases at an early stage. This proactive approach enhances the market demand for anti-rheumatics, as timely intervention necessitates medication for symptom management and disease modification.

ANTI-RHEUMATICS INDUSTRY SEGMENTATION:

Breakup by Type:

  • Prescription-based Drugs
  • Over-the-Counter Drugs

Prescription-based drugs account for the majority of the market share

Breakup by Drug Class:

  • Disease Modifying Anti-Rheumatics Drugs (DMARD's)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
  • Corticosteroids
  • Uric Acid Drugs
  • Others

Disease modifying anti-rheumatics drugs (DMARD's) hold the largest share in the industry

Breakup by Route of Drug Administration:

  • Oral
  • Parenteral
  • Others

Parenteral represents the leading market segment

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • E-Commerce

Hospital pharmacies exhibit a clear dominance in the market

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest anti-rheumatics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share since the region is a hub for pharmaceutical research and development (R&D). Additionally, North America, particularly the United States, has a well-established healthcare system equipped with state-of-the-art medical facilities. This superior infrastructure allows for the early diagnosis and comprehensive treatment of rheumatic diseases, which naturally leads to a higher demand for anti-rheumatic medications. Along with this, the widespread availability of specialized rheumatology clinics and medical professionals further drives the need for these drugs. Apart from this, the regulatory environment in North America, led by agencies like the U.S. Food and Drug Administration (FDA), is highly supportive of medical advancements. Furthermore, the increasing aging population in the region is driving the demand for anti-rheumatics.

COMPETITIVE LANDSCAPE:

Companies are investing heavily in the development of new anti-rheumatic drugs, targeting existing and emerging therapeutic mechanisms. Additionally, many companies are entering into partnerships, mergers, and acquisitions. These strategic collaborations often involve sharing technology, resources, and market channels. Apart from this, they are also focusing on expanding market access through various channels. This often involves launching products in new geographical markets, increasing production capacities, or diversifying supply chains to ensure more reliable distribution. Furthermore, various companies are using analytics to identify market trends, patient preferences, and treatment outcomes. Moreover, they are investing in educational programs for healthcare providers, patients, and the public.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celltrion Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnsons
  • Pfizer Inc.
  • Sanofi SA

Key Questions Answered in This Report

  • 1.What was the size of the global anti-rheumatics market in 2025?
  • 2.What is the expected growth rate of the global anti-rheumatics market during 2026-2034?
  • 3.What are the key factors driving the global anti-rheumatics market?
  • 4.What has been the impact of COVID-19 on the global anti-rheumatics market?
  • 5.What is the breakup of the global anti-rheumatics market based on the type?
  • 6.What is the breakup of the global anti-rheumatics market based on the drug class?
  • 7.What is the breakup of the global anti-rheumatics market based on the route of drug administration?
  • 8.What is the breakup of the global anti-rheumatics market based on the distribution channel?
  • 9.What are the key regions in the global anti-rheumatics market?
  • 10.Who are the key players/companies in the global anti-rheumatics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anti-Rheumatics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription-based Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-Counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Disease Modifying Anti-Rheumatics Drugs (DMARD's)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Nonsteroidal Anti-Inflammatory Drugs (NSAID's)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Corticosteroids
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Uric Acid Drugs
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Route of Drug Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Parenteral
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 E-Commerce
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 AstraZeneca plc
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Biogen Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Bristol-Myers Squibb Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Celltrion Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Eli Lilly and Company
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 F. Hoffmann-La Roche AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
    • 15.3.9 Johnson & Johnsons
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi SA
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Anti-Rheumatics Market: Major Drivers and Challenges
  • Figure 2: Global: Anti-Rheumatics Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Anti-Rheumatics Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Anti-Rheumatics Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Anti-Rheumatics Market: Breakup by Drug Class (in %), 2025
  • Figure 6: Global: Anti-Rheumatics Market: Breakup by Route of Drug Administration (in %), 2025
  • Figure 7: Global: Anti-Rheumatics Market: Breakup by Distribution Channel (in %), 2025
  • Figure 8: Global: Anti-Rheumatics Market: Breakup by Region (in %), 2025
  • Figure 9: Global: Anti-Rheumatics (Prescription-based Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Anti-Rheumatics (Prescription-based Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Anti-Rheumatics (Over-the-Counter Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Anti-Rheumatics (Disease Modifying Anti-Rheumatics Drugs (DMARD's)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Anti-Rheumatics (Nonsteroidal Anti-Inflammatory Drugs (NSAID's)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Anti-Rheumatics (Corticosteroids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Anti-Rheumatics (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Anti-Rheumatics (Uric Acid Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Anti-Rheumatics (Uric Acid Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Anti-Rheumatics (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Anti-Rheumatics (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Anti-Rheumatics (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Anti-Rheumatics (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Anti-Rheumatics (Parenteral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Anti-Rheumatics (Parenteral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Anti-Rheumatics (Other Routes of Drug Administration) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Global: Anti-Rheumatics (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Global: Anti-Rheumatics (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Global: Anti-Rheumatics (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Global: Anti-Rheumatics (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Global: Anti-Rheumatics (E-Commerce) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Global: Anti-Rheumatics (E-Commerce) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: North America: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: North America: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: United States: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: United States: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Canada: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Canada: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Asia-Pacific: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Asia-Pacific: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: China: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: China: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Japan: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Japan: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: India: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: India: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: South Korea: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: South Korea: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Australia: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Australia: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Indonesia: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Indonesia: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Others: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Europe: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Europe: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Germany: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Germany: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: France: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: France: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: United Kingdom: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: United Kingdom: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Italy: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Italy: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Spain: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Spain: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Russia: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Russia: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Others: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Latin America: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Latin America: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Brazil: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Brazil: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Mexico: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 78: Mexico: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 79: Others: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 80: Others: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 81: Middle East and Africa: Anti-Rheumatics Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 82: Middle East and Africa: Anti-Rheumatics Market: Breakup by Country (in %), 2025
  • Figure 83: Middle East and Africa: Anti-Rheumatics Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Global: Anti-Rheumatics Industry: SWOT Analysis
  • Figure 85: Global: Anti-Rheumatics Industry: Value Chain Analysis
  • Figure 86: Global: Anti-Rheumatics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Anti-Rheumatics Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Anti-Rheumatics Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Anti-Rheumatics Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 4: Global: Anti-Rheumatics Market Forecast: Breakup by Route of Drug Administration (in Million USD), 2026-2034
  • Table 5: Global: Anti-Rheumatics Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Anti-Rheumatics Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Anti-Rheumatics Market: Competitive Structure
  • Table 8: Global: Anti-Rheumatics Market: Key Players